{"id":617562,"date":"2022-09-20T20:16:01","date_gmt":"2022-09-20T20:16:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=617562"},"modified":"2022-09-20T20:16:01","modified_gmt":"2022-09-20T20:16:01","slug":"acral-lentiginous-melanoma-market-to-witness-growth-by-20222032-estimates-delveinsight-key-companies-atreca-bristolmyers-squibb-pfizer-novartis","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/acral-lentiginous-melanoma-market-to-witness-growth-by-20222032-estimates-delveinsight-key-companies-atreca-bristolmyers-squibb-pfizer-novartis_617562.html","title":{"rendered":"Acral Lentiginous Melanoma Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies &#8211; Atreca, Bristol-Myers Squibb, Pfizer, Novartis"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1663677298.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Acral Lentiginous Melanoma Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies - Atreca, Bristol-Myers Squibb, Pfizer, Novartis\" src=\"https:\/\/www.abnewswire.com\/uploads\/1663677298.jpeg\" alt=\"Acral Lentiginous Melanoma Market to Witness Growth by (2022-2032), Estimates DelveInsight | Key Companies - Atreca, Bristol-Myers Squibb, Pfizer, Novartis\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cAcral Lentiginous Melanoma Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Acral Lentiginous Melanoma, historical and forecasted epidemiology as well as the Acral Lentiginous Melanoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">The<strong> <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/acral-lentiginous-melanoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Acral Lentiginous Melanoma market<\/a><\/strong> is expected to surge due to the disease&#8217;s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Acral Lentiginous Melanoma pipeline products will significantly revolutionize the Acral Lentiginous Melanoma market dynamics.&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acral Lentiginous Melanoma Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">According to AIM at Melanoma Foundation, Acral Lentiginous Melanoma (ALM) is a type of melanoma that appears on the palms of the hands, the soles of the feet, or under the nails. The term &ldquo;acral&rdquo; refers to the occurrence of melanoma on the palms or soles. The word&ldquo;lentiginous&rdquo; means that the spot of melanoma is much darker than the surrounding skin; it has a sharp border between the dark skin and the lighter skin around it. The contrast in color is one of the most noticeable symptoms of acral lentiginous melanoma.<\/p>\n<p style=\"text-align: justify;\">Acral Lentiginous Melanoma starts as a slowly-enlarging flat patch of discolored skin. At first, the malignant cells remain within the epidermis&mdash;the in situ phases of melanoma, which can persist for months or year.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of the key facts of the Acral Lentiginous Melanoma Market Report:&nbsp;<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The Acral Lentiginous Melanoma market size is anticipated to grow with a significant <strong>CAGR<\/strong> during the study period <strong>(2019-2032)&nbsp;<\/strong><\/li>\n<li>Acral Lentiginous Melanoma, is most commonly diagnosed in people over age <strong>40<\/strong>, and affects men and women of all skin colors equally. It is the fourth most common subtype of melanoma, with an estimated frequency of <strong>2\u20125%<\/strong> of all melanomas&nbsp;<\/li>\n<li>According to the study conducted by <strong>Bradford et al.<\/strong> titled &ldquo;Acral lentiginous melanoma: Incidence and survival patterns in the United States,&rdquo; the overall age-adjusted incidence rate was 1.8 per million persons.&nbsp;<\/li>\n<li><strong>Key Acral Lentiginous Melanoma Companies:<\/strong> Atreca, Bristol-Myers Squibb, Pfizer, Novartis, and others&nbsp;<\/li>\n<li><strong>Key Acral Lentiginous Melanoma Therapies:<\/strong> ATRC-101, Nivolumab with Ipilimumab, Sunitinib, Imatinib, and others&nbsp;<\/li>\n<li>The Acral Lentiginous Melanoma epidemiology based on gender analyzed that, Acral Lentiginous Melanoma is equally common in males and females<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Get a Free sample for the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acral-lentiginous-melanoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Acral Lentiginous Melanoma Market Report<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key benefits of the Acral Lentiginous Melanoma Market report:<\/strong><\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Acral Lentiginous Melanoma market report covers a descriptive overview and comprehensive insight of the Acral Lentiginous Melanoma Epidemiology and Acral Lentiginous Melanoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Acral Lentiginous Melanoma market report provides insights on the current and emerging therapies.<\/li>\n<li>Acral Lentiginous Melanoma market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Acral Lentiginous Melanoma market report offers an edge that will help develop business strategies by understanding trends shaping and driving the Acral Lentiginous Melanoma market.<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Acral Lentiginous Melanoma market share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acral-lentiginous-melanoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Acral Lentiginous Melanoma market forecast<\/a>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acral Lentiginous Melanoma Epidemiology Segmentation:<\/strong><\/p>\n<p style=\"text-align: justify;\">The Acral Lentiginous Melanoma market report proffers epidemiological analysis for the study period 2019&ndash;2032 in the 7MM segmented into:<\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Prevalence of Acral Lentiginous Melanoma<\/li>\n<li>Prevalent Cases of Acral Lentiginous Melanoma by severity<\/li>\n<li>Gender-specific Prevalence of Acral Lentiginous Melanoma<\/li>\n<li>Diagnosed Cases of Episodic and Chronic Acral Lentiginous Melanoma&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acral Lentiginous Melanoma Market &nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">The dynamics of the Acral Lentiginous Melanoma market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as A<strong>TRC-101, Nivolumab with Ipilimumab<\/strong>, and others during the forecasted period 2019-2032.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Acral Lentiginous Melanoma epidemiology trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acral-lentiginous-melanoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Acral Lentiginous Melanoma Epidemiological Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Acral Lentiginous Melanoma Therapies and Key Companies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>ATRC-101:<\/strong> Atreca<\/li>\n<li><strong>Nivolumab with Ipilimumab:<\/strong> Bristol-Myers Squibb<\/li>\n<li><strong>Sunitinib:<\/strong> Pfizer<\/li>\n<li><strong>Imatinib:&nbsp;<\/strong> Novartis<\/li>\n<li><strong>Tebentafusp:<\/strong> AstraZeneca&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Acral Lentiginous Melanoma Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li><strong>Study Period: 2019&ndash;2032<\/strong><\/li>\n<li><strong>Coverage:<\/strong> 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]<\/li>\n<li><strong>Key Acral Lentiginous Melanoma Companies:<\/strong> Atreca, Bristol-Myers Squibb, Pfizer, Novartis, and others<\/li>\n<li><strong>Key Acral Lentiginous Melanoma Therapies:<\/strong> ATRC-101, Nivolumab with Ipilimumab, Sunitinib, Imatinib, and others<\/li>\n<li><strong>Acral Lentiginous Melanoma Therapeutic Assessment:<\/strong> Acral Lentiginous Melanoma current marketed and Acral Lentiginous Melanoma emerging therapies<\/li>\n<li><strong>Acral Lentiginous Melanoma Market Dynamics:&nbsp;<\/strong> Acral Lentiginous Melanoma market drivers and barriers&nbsp;<\/li>\n<li><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis, PESTLE analysis, Porter&rsquo;s five forces, BCG Matrix, Market entry strategies<\/li>\n<li><strong>Unmet Needs, KOL&rsquo;s views, Analyst&rsquo;s views, Acral Lentiginous Melanoma&nbsp; Market Access and Reimbursement<\/strong><\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Acral Lentiginous Melanoma Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary for Acral Lentiginous Melanoma<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis of Acral Lentiginous Melanoma<\/p>\n<p style=\"text-align: justify;\">4. Acral Lentiginous Melanoma Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Acral Lentiginous Melanoma Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Acral Lentiginous Melanoma Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Acral Lentiginous Melanoma Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Acral Lentiginous Melanoma&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Acral Lentiginous Melanoma Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Acral Lentiginous Melanoma Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Acral Lentiginous Melanoma Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Acral Lentiginous Melanoma Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Acral Lentiginous Melanoma Market Analysis (2019&ndash;2032)<\/p>\n<p style=\"text-align: justify;\">14. Acral Lentiginous Melanoma Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Acral Lentiginous Melanoma Market drivers<\/p>\n<p style=\"text-align: justify;\">16. Acral Lentiginous Melanoma Market barriers<\/p>\n<p style=\"text-align: justify;\">17.&nbsp; Acral Lentiginous Melanoma Appendix<\/p>\n<p style=\"text-align: justify;\">18. Acral Lentiginous Melanoma Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Acral Lentiginous Melanoma treatment, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/acral-lentiginous-melanoma-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Acral Lentiginous Melanoma Medications<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_75707.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=acral-lentiginous-melanoma-market-to-witness-growth-by-20222032-estimates-delveinsight-key-companies-atreca-bristolmyers-squibb-pfizer-novartis\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> Nevada<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=acral-lentiginous-melanoma-market-to-witness-growth-by-20222032-estimates-delveinsight-key-companies-atreca-bristolmyers-squibb-pfizer-novartis\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight\u2019s \u201cAcral Lentiginous Melanoma Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of the Acral Lentiginous Melanoma, historical and forecasted epidemiology as well as the Acral Lentiginous Melanoma market trends in the United States, EU5 (Germany, Spain, &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/acral-lentiginous-melanoma-market-to-witness-growth-by-20222032-estimates-delveinsight-key-companies-atreca-bristolmyers-squibb-pfizer-novartis_617562.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-617562","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/617562","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=617562"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/617562\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=617562"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=617562"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=617562"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}